{"id":"W4286294580","doi":"10.1200/jco.2022.40.16_suppl.tps9146","title":"EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non–small cell lung cancer (NSCLC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"Gilead Sciences","keywords":"Medicine; Carboplatin; Lung cancer; Internal medicine; Chemotherapy; Oncology; Pembrolizumab; Cisplatin; Cancer; Phases of clinical research; Paclitaxel; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001573351,0.001980543,0.00153237,0.0004746293,0.0003270267,0.001381999,0.001579768,0.001745303,0.006603158],"category_scores_gemma":[0.0008494625,0.0008339019,0.001326461,0.0004228344,0.001031179,0.001293094,0.0004974595,0.003808747,0.001551729],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009597336,"about_ca_system_score_gemma":0.001492147,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009705469,"about_ca_topic_score_gemma":0.003521022,"domain_scores_codex":[0.9996684,0.0001381289,0.00001213688,0.00006862439,0.00003877604,0.00007395975],"domain_scores_gemma":[0.9996082,0.00005022162,0.00006899075,0.00003633494,0.00003535881,0.0002008748],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5204492,0.2378271,0.005213209,0.003096193,0.002579324,0.0004236015,0.000641124,0.004971472,0.08151932,0.001164298,0.01238557,0.1297297],"study_design_scores_gemma":[0.5649565,0.4128228,0.005730263,0.00008841008,0.0008060266,0.0005704013,0.0001581839,0.001605166,0.00594386,0.000416112,0.006844672,0.00005761926],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9836386,0.002881469,0.001124159,0.0007295705,0.0003107666,0.00549879,0.002110915,0.0002378518,0.003467918],"genre_scores_gemma":[0.9733639,0.003894528,0.002748027,0.001906451,0.0002503688,0.005797528,0.004692047,0.0001201224,0.007226944],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006603158,"threshold_uncertainty_score":0.02208972,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0822613191702985,"score_gpt":0.44876321393303,"score_spread":0.3665018947627315,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}